New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:07 EDTINSYTop prescriber of Insys drug probed for fraud, MLive says
Dr. Gavin Awerbuch, a neurologist that was paid $6.9M from 2009, through Feb. 6, 2014, for his prescriptions of Insys Therapeutics' cancer pain drug Subsys, was arraigned in federal court in Detroit on May 6 on charges of health care fraud, reported MLive yesterday. "Awerbuch is responsible for approximately 20.3% of the Subsys prescribed to Medicare beneficiaries nationwide during this time," the affidavit stated, according to the report. Shares of Insys were down more than 16% today. Reference Link
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
06:51 EDTINSYInsys Therapeutics enrolls first patient for Phase II study of CBD
Insys Therapeutics announced that the Company has enrolled the first patient in a Phase II clinical study for the treatment of infantile spasms using its pharmaceutical CBD product candidate.
February 1, 2016
08:14 EDTINSYInsys Therapeutics longer term outlook stable, says RBC Capital
After surveying 40 doctors, including nine who prescribed large amounts of Insys' Subsys, RBC Capital says that payor pushback on the drug is "limited," while 95% of all the doctors surveyed and 89% of the high prescribers "intend to write as many or more Subsys prescriptions this year" as last year. The firm thinks the stock's valuation is attractive following its 61% pullback since July. It trimmed its price target on the stock to $44 from $49 but keeps an Outperform rating. .

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use